Latest News in the pharma Industry

Research & Development

Biogen and Sobi receive positive opinion from CHMP for Elocta (rFVIIIFc) for the treatment of hemophilia A

Biogen and Sobi receive positive opinion from CHMP for Elocta (rFVIIIFc) for the treatment of hemophilia A

25 Sep 2015

Elocta is a recombinant factor VIII Fc fusion protein product for the treatment of hemophilia A that, if approved, would be the first hemophilia A treatment with prolonged circulation available in the EU.

Read more 
NMI TT Pharmaservices establishes new branch in Berlin

NMI TT Pharmaservices establishes new branch in Berlin

25 Sep 2015

The new outstation will provide life science researchers with the company's proprietary DigiWest multiplex protein profiling services, to accelerate lead characterisation, disease mechanism and drug mode-of-action analyses, as well as biomarker identif...

Read more 
Charity and academic collaboration aims to find drug treatment for lymphoma

Charity and academic collaboration aims to find drug treatment for lymphoma

24 Sep 2015

MALT1 could be a promising drug target for some subsets of lymphoma, including diffuse large B cell lymphoma.

Read more 
Bausch + Lomb and Nicox announce FDA Acceptance of NDA for novel glaucoma candidate

Bausch + Lomb and Nicox announce FDA Acceptance of NDA for novel glaucoma candidate

22 Sep 2015

If approved, Vesneo will be the first nitric oxide donating prostaglandin receptor agonist available for patients with open angle glaucoma or ocular hypertension.

Read more 
Targeting DNA — protein-based sensor could detect viral infection or kill cancer cells

Targeting DNA — protein-based sensor could detect viral infection or kill cancer cells

21 Sep 2015

MIT biological engineers have developed a modular system of proteins that can detect a particular DNA sequence in a cell and then trigger a specific response, such as cell death.

Read more 
Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola

Regeneron announces agreement with BARDA for the development of new antibody treatment for Ebola

21 Sep 2015

HHS will provide initial funding of approximately $17 million to support preclinical development and antibody manufacturing. This initial funding is designed to support an Investigational New Drug application with the FDA.

Read more 
Jardiance is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

Jardiance is the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial

18 Sep 2015

Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company's Jardiance (empagliflozin) significantly reduced the risk of the combined endpoint of cardiovascular (CV) death, non-fatal heart attack or non-fatal stroke by 14% when added to standard of...

Read more 
Victoza (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial

Victoza (liraglutide) provides significantly greater HbA1c reduction than lixisenatide in new clinical trial

17 Sep 2015

Findings from a head-to-head trial comparing Victoza (liraglutide) and lixisenatide, both in combination with metformin, demonstrated a significantly greater reduction in HbA1c of -1.83% for liraglutide vs -1.21% for lixisenatide in adults with type 2 ...

Read more 
CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP GT technology

CEVEC and Généthon sign a collaboration agreement to develop lentiviral vector packaging cell lines based on CEVEC’s proprietary CAP GT technology

17 Sep 2015

Agreement enables fully scalable, industrial lentivirus vector production

Read more 
Merck's omarigliptin achieved similar A1C reductions to Januvia in patients with type 2 diabetes inadequately controlled on Metformin monotherapy

Merck's omarigliptin achieved similar A1C reductions to Januvia in patients with type 2 diabetes inadequately controlled on Metformin monotherapy

17 Sep 2015

Omarigliptin was found to be non-inferior to Merck’s once-daily DPP-4 inhibitor, Januvia (sitagliptin), at reducing patients’ A1C levels from baseline, with similar A1C reductions achieved in both groups.

Read more 
Using proteomics to understand how genetic mutations rewire cancer cells

Using proteomics to understand how genetic mutations rewire cancer cells

17 Sep 2015

Scientific publications highlight studies using data from Thermo Scientific Orbitrap mass spectrometry and next-generation sequencing to discover how cancer attacks the protein networks controlling human cells

Read more 
BMS’s Opdivo (nivolumab) receives breakthrough therapy designation from FDA for advanced renal cell carcinoma

BMS’s Opdivo (nivolumab) receives breakthrough therapy designation from FDA for advanced renal cell carcinoma

16 Sep 2015

This is the fourth Breakthrough Therapy Designation granted for Opdivo by the FDA

Read more